TRC Plus for Hereditary Angioedema
Total cost and care for Hereditary Angioedema (HAE)
HAE is a rare, often hereditary swelling condition that affects 6,000 patients in the U.S. Due to many variables, HAE can be unpredictable for plan sponsors, making it difficult to budget costs and ensure patients are on the right combination of treatments.
TRC Plus is redefining care for HAE patients
Ensure the best care for patients and better manage overall HAE costs with capabilities such as:
HAE Grand Rounds
is a collaborative clinical approach through our HAE TRC to reviewing patient cases, allowing our pharmacists to offer recommendations to prescribers that are accepted across specialty disciplines more than 50% of the time.1
Accredo One AdherenceTM
which tracks medication usage through a wifi-enabled syringe disposal device and includes patient dose reminder texts and follow ups from Accredo nurses.
HAE therapy discounts
across the HAE therapy class with an average monthly savings of $10,000.
Custom reporting
on plan-specific spend estimates across all HAE therapies and a self-service dashboard to review therapy utilization.
Source
- Accredo clinical studies compiled from 2013-2023.